BIO staff recently traveled to Geneva to brief country missions and representatives from the World Health Organization (WHO), World Trade Organization (WTO) and World Intellectual Property Organization (WIPO) on the science behind developing somatic cell genome editing medicine and its potential treat and cure disease.
Matt O’Mara, BIO’s Vice President of International Affairs and Trade Policy and Sesquile Ramon, BIO’s Director, Science and Regulatory Affairs briefed the global audience on BIO’s position on Human Genome Editing and overviewed the basics behind the science of treating and preventing genetically defined human diseases
Read more about BIO’s position on Genome Editing
More From This Author
